ArticleACS pharmacology & translational science2021
Transcriptomic Analysis of the Activity and Mechanism of Action of a Ruthenium(II)-Based Antimicrobial That Induces Minimal Evolution of Pathogen Resistance.
Article in ACS pharmacology & translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Broad-Spectrum Antimicrobial Activity of a Ruthenium(II) Polypyridyl Complex against Multidrug-Resistant Uropathogens and Biofilms.ACS omega · 2026Article
- Surface-Functionalised Copper Oxide Nanoparticles: A Pathway to Multidrug-Resistant Pathogen Control in Medical Devices.Nanomaterials (Basel, Switzerland) · 2024Article
- In Vitro and In Vivo Studies on a Mononuclear Ruthenium Complex Reveals It is a Highly Effective, Fast-Acting, Broad-Spectrum Antimicrobial in Physiologically Relevant Conditions.ACS infectious diseases · 2024Article
- Tetrandrine Derivatives as Promising Antibacterial Agents.ACS omega · 2023Article
- Multi-target antibacterial mechanism of ruthenium polypyridine complexes with anthraquinone groups againstRSC medicinal chemistry · 2023Article
- Metals to combat antimicrobial resistance.Nature reviews. Chemistry · 2023Review
- Clearing an ESKAPE Pathogen in a Model Organism; A Polypyridyl Ruthenium(II) Complex Theranostic that Treats a Resistant Acinetobacter baumannii Infection in Galleria mellonella.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Article
- Ruthenium polypyridine complexes with triphenylamine groups as antibacterial agents againstFrontiers in chemistry · 2022Article
- Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Increasing concern over rising levels of antibiotic resistance among pathogenic bacteria has prompted significant research into developing efficacious alternatives to antibiotic treatment. Previously, we have reported on the therapeutic activity of a dinuclear ruthenium(II) complex against pathogenic, multi-drug-resistant bacterial pathogens. Herein, we report that the solubility properties of this lead are comparable to those exhibited by orally available therapeutics that in comparison to clinically relevant antibiotics it induces very slow evolution of resistance in the uropathogenic, therapeutically resistant,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.